Last updated: July 17, 2026
Litigation Summary and Patent Infringement Analysis for Unimed Pharmaceuticals LLC v. Lupin Atlantis Holdings SA (1:15-cv-00904)
Executive summary
Unimed Pharmaceuticals LLC v. Lupin Atlantis Holdings SA (1:15-cv-00904) is a 2015 Hatch-Waxman patent infringement action in which Unimed asserted Orange Book-listed patents against Lupin tied to a generic launch risk. The case posture and substantive infringement issues are governed by the asserted patent claims and Lupin’s Paragraph IV theory (or non-infringement/invalidity defenses), with the scope of any injunction tied to the specific formulation, method-of-use, or manufacturing claims at issue. A complete litigation summary with claim-level construction, holdings, and enforcement outcome cannot be produced from the case identifier alone.
What happened in Unimed v. Lupin Atlantis Holdings SA (1:15-cv-00904)?
Answer: A patent infringement lawsuit was filed in 2015 by Unimed Pharmaceuticals LLC against Lupin Atlantis Holdings SA, asserting that Lupin’s proposed generic product would infringe one or more Orange Book-listed patents.
Case metadata
- Case number: 1:15-cv-00904
- Parties: Unimed Pharmaceuticals LLC (plaintiff) vs. Lupin Atlantis Holdings SA (defendant)
Typical Hatch-Waxman litigation mechanics implicated
Without the docket text, complaint, or court orders, the specific mechanics cannot be fixed to a verified chronology. In this case type, the record usually contains:
- Complaint alleging infringement of specific patent numbers and claims
- Defendant’s response asserting non-infringement, invalidity, and possibly unenforceability defenses
- Claims on whether Lupin’s filing is a Paragraph IV certification that the asserted patents are invalid, unenforceable, or not infringed
- Motions that may include claim construction and summary judgment
Which patents were asserted, and how did Lupin challenge them?
Answer: The asserted patents and the specific invalidity and non-infringement theories cannot be stated accurately from the case identifier provided.
What to extract from the complaint and Markman record (what drives outcomes)
In order to analyze strength and litigation exposure, the key items are:
- Asserted patent numbers
- Asserted claim(s) (independent claim scope plus dependent claim “hooks”)
- Alleged infringement basis (e.g., product composition, formulation parameters, dosing regimen, method-of-use steps)
- Lupin defenses:
- Invalidity: anticipation, obviousness, lack of written description/enablement, indefiniteness
- Non-infringement: design-around elements missing from the proposed product
- Unenforceability: inequitable conduct is occasionally pleaded
- Any narrowing based on claim construction
What did the court decide in Unimed v. Lupin Atlantis (1:15-cv-00904)?
Answer: Court rulings (dismissal, claim construction outcomes, summary judgment, injunction, stay/lift events, trial result) cannot be determined without docket orders or published opinions.
Outcomes that materially change business risk
Patent litigation outcomes affect:
- Whether a 90-day notice of Paragraph IV triggers remedies
- Whether the court enters a permanent injunction or later converts it based on findings
- Settlement terms that may include design-around authorization, launch timing, or license payments
- The effect on exclusivity timing and FDA approval-to-launch sequencing
Settlement and injunction: did the parties reach a deal?
Answer: Settlement status and any agreement terms cannot be stated from the case number alone.
What a settlement in this setting typically covers
Where Hatch-Waxman cases settle, agreements usually specify:
- Launch date windows
- Carve-outs for non-infringing formulations or dosage forms
- Cross-licenses and covenant-not-to-sue terms
- Patent list schedules and “most favored nation” style clauses (varies by deal)
- FDA prosecution commitments (less common in public summaries)
How strong was Unimed’s patent position in this dispute?
Answer: Patent strength cannot be quantified without:
- asserted patent list
- claim construction results
- infringement/invalidity findings
- prosecution history that drives estoppel or claim scope limits
Strength indicators typically evaluated
When analyzing estate strength for investment or licensing, the decisive factors are:
- Whether independent claims survive invalidity challenges at the time of dispositive rulings
- How claim construction narrows the claim elements compared with the accused product
- Whether the court limits scope based on specification or prosecution history
- Whether prior art references are repeatedly used against the asserted claims in the record
What generic entry risks exist for Lupin under the litigation record?
Answer: Entry risk depends on the final adjudication or settlement, which cannot be verified from the case identifier alone.
Risk drivers
- If patents are found valid and infringed, launch is typically blocked absent design-around or further license.
- If patents are found invalid or not infringed, risk shifts to FDA labeling, at-risk distribution, and potential appeal outcomes.
- If a settlement includes timing restrictions, launch is contractually constrained regardless of later patent litigation outcomes.
How does this case compare with other Unimed v. generic competitors?
Answer: A comparative analysis cannot be completed without identifying:
- the drug(s) at issue in 1:15-cv-00904
- the patent set
- the procedural posture and outcome
- the settlement terms or court holdings
Docket-driven timeline (what can be built when orders are known)
Answer: A verified timeline cannot be produced without docket entries, filings, or court orders.
Typical timeline elements (for this case type)
- Filing date: 2015 (exact date needs docket)
- Service and answer deadlines
- Claim construction schedule
- Summary judgment or motion practice deadlines
- Trial and final judgment dates or settlement dates
Key takeaways
- Unimed Pharmaceuticals LLC sued Lupin Atlantis Holdings SA in a Hatch-Waxman framework under case number 1:15-cv-00904.
- The litigation risk profile is determined by the asserted patent list, claim scope, and court rulings (or settlement terms).
- A complete litigation summary with claim-level analysis, outcome, and business impact cannot be produced from the case number alone.
FAQs
- What is a Paragraph IV certification in Hatch-Waxman cases like Unimed v. Lupin Atlantis?
- How do claim construction rulings typically affect generic non-infringement defenses?
- What remedies can a patentee seek in federal patent infringement actions tied to ANDA filings?
- How do settlement agreements in generic patent cases impact launch timing and design-arounds?
- What is the Orange Book’s role in determining which patents are asserted in Hatch-Waxman litigation?
References
- Unimed Pharmaceuticals LLC v. Lupin Atlantis Holdings SA, 1:15-cv-00904 (case docket identifier provided by user).
